A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma

• Sponsor: Boston Scientific Corporation (Industry)
• Overall Status: Terminated
• CT.gov ID: NCT00479765
• Collaborator: (none)
• Enrollment: 4
• Locations: 5
• Arm: 1
• Duration (Months): 31
• Patients Per Site: 0.8
• Patients Per Site Per Month: 0

Study Details

Study Description

Brief Summary

OncoGel™ is a new, experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel™) over a long period of time. The gel will disappear in 4 to 6 weeks as it releases the paclitaxel.

The purpose of this study is to evaluate the safety and tolerability of OncoGel when placed into the tumor resection cavity in the brain following surgical removal of the tumor. Dose escalation is conducted by gradually increasing the amount of OncoGel placed in the resection cavity in small groups of patients, and watching the patients closely for side effects before moving to the next dose level. The study will also test whether OncoGel helps to prevent or delay the tumor from regrowing.

Condition or Disease	Intervention/Treatment	Phase
Glioblastoma Multiforme; Brain Neoplasms	Drug: OncoGel (ReGel/Paclitaxel)	Phase 1/Phase 2

Detailed Description

This study is for patients with recurrent glioblastoma multiforme. Because most recurrences are in the area of the original resection, local delivery of a chemotherapeutic agent may prevent or delay additional recurrences. Paclitaxel has demonstrated activity against 9L glioma tumor lines, but has poor central nervous system penetration after intravenous administration. OncoGel is a new formulation of paclitaxel in a bioerodible gel that can be administered directly to the brain, thereby bypassing the blood-brain barrier.

Study Design

• Study Type: Interventional
• Actual Enrollment: 4 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma
• Study Start Date: Mar 1, 2007
• Actual Primary Completion Date: Oct 1, 2009
• Actual Study Completion Date: Oct 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 1 OncoGel administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel	Drug: OncoGel (ReGel/Paclitaxel); OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.

Outcome Measures

Primary Outcome Measures

1. Occurence of Dose-limiting Toxicities (DLTs) [8 weeks]

   any evidence or sign of a dose-limiting toxicity after administration to determine the maximum tolerated dose (MTD)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• At least 18 to less than 70 years of age

• Radiological evidence on MRI of progressive recurrent malignant glioma that is unilateral, unifocal, supratentorial and of the minimum tumor volume as required per dose level assignment

• Tumor must have a solid contrast enhancing component

• Gross total resection >95% of the recurrence must be planned

• Must have received prior conventional radiation therapy completed >4 weeks before Study Day 1 (ie, day of craniotomy and OncoGel administration)

• Previous cytoreductive surgery or biopsy with pathologic diagnosis of glioblastoma multiforme

• Diagnosis of glioma at the time of debulking surgery for recurrence (by frozen section or squash preparation)

• Life expectancy > 2 months

• KPS greater than or equal to 70

• Using appropriate birth control, if female of child-bearing potential;

• Able and willing to participate in the study by signing the informed consent document

Exclusion Criteria:

• Contrast-enhancing tumor crossing the midline

• Multifocal or non-contiguous tumor resulting in multiple resection cavities

• Evidence of tumor dissemination (ependymal, leptomeningeal)

• Tumors that result in a lobectomy or after resection leave an insufficient residual cavity to receive the expected OncoGel volume

• Expected communication between the ventricle and resection cavity that cannot be repaired

• Involvement of primary sensorimotor cortex in the dominant hemisphere or within 1.5 cm of the optic chiasm, either optic nerve or any other cranial nerve

• Significantly increased intracranial pressure

• Received any type of stereotactic radiosurgery or brachytherapy with the exception of a stereotactic radiosurgery boost as part of the initial radiation therapy

• History of seizures refractory to two or more anticonvulsant medications co-administered at therapeutic levels

• Impaired organ function as evidenced by clinically significant laboratory parameters including but not limited to the following: Hepatic Status: Bilirubin >2.0 mg/dL; Aspartate transaminase (AST) >2.5 times the normal limit; Alanine aminotransferase (ALT) >2.5 times the normal limit. Hematopoietic Status: Absolute neutrophil count (ANC) <1500mm3; Platelet count <100,000/mm3; Hemoglobin < 10 g/dL. Hemostatic: Prothrombin Time (PT) or INR above normal range; Partial Thromboplastin Time (PTT) above normal range; Bleeding Time outside normal range (if performed by hospital). Renal Status: Serum creatinine >2 mg/dL.

• Contraindication to MRI

• Receipt any chemotherapeutic agent within 28 days of Study Day 1 or nitrosourea within 6 weeks of Study Day 1

• Received any intracerebral investigational agent

• Receipt of another investigational drug or device within 28 days of the planned surgery

• Known history of allergy to paclitaxel or any other component of OncoGel

• Pregnant or lactating

• Concurrent life-threatening disease

• Any medical condition or other circumstance that, in the opinion of the Investigator, would make the subject unlikely or unable to successfully complete the study, or would interfere with analysis of study results

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The University of Chicago Brain Tumor Center	Chicago	Illinois	United States	60637
2	The Johns Hopkins University	Baltimore	Maryland	United States	21231
3	University of Rochester Medical Center	Rochester	New York	United States	14642
4	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	United States	27599
5	Vanderbilt University Medical Center	Nashville	Tennessee	United States	37212

Sponsors and Collaborators

• Boston Scientific Corporation

Investigators

• Principal Investigator: Maciej S Lesniak, MD, University of Chicago

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Boston Scientific Corporation
• ClinicalTrials.gov Identifier: NCT00479765
• Other Study ID Numbers: PR016-CLN-pro002; OGL-109
• First Posted: May 28, 2007
• Last Update Posted: Jun 22, 2022
• Last Verified: Jun 1, 2022

• Keywords provided by Boston Scientific Corporation: glioblastoma multiforme; recurrent; Phase 1; Phase 2; Phase I; Phase II; brain; cancer; paclitaxel; intracranial; tumor; local; chemotherapy; brain tumor; brain cancer; glioma; OncoGel
• Additional relevant MeSH terms: Glioblastoma; Glioma; Brain Neoplasms; Paclitaxel

Study Results

Participant Flow

Arm/Group Title	OncoGel
Arm/Group Description	OncoGel administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel OncoGel (ReGel/Paclitaxel): OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
Period Title: Overall Study
STARTED	4
COMPLETED	0
NOT COMPLETED	4

Baseline Characteristics

Arm/Group Title	OncoGel 5mL
Arm/Group Description	OncoGel 5 mL administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel OncoGel (ReGel/Paclitaxel): OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
Overall Participants	4
Age (years) [Mean (Full Range) ]
Mean (Full Range) [years]	60
Sex: Female, Male (Count of Participants)
Female	0 0%
Male	4 100%

Outcome Measures

1. Primary Outcome

Title	Occurence of Dose-limiting Toxicities (DLTs)
Description	any evidence or sign of a dose-limiting toxicity after administration to determine the maximum tolerated dose (MTD)
Time Frame	8 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	OncoGel 5mL
Arm/Group Description	OncoGel 5 mL administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel OncoGel (ReGel/Paclitaxel): OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
Measure Participants	4
Number [dose limiting toxicities]	0

Adverse Events

Arm/Group Title	OncoGel 5mL
Arm/Group Description	OncoGel 5 mL administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel OncoGel (ReGel/Paclitaxel): OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
All Cause Mortality
	OncoGel 5mL
	Affected / at Risk (%)	# Events
Total	/ (NaN)
Serious Adverse Events
	OncoGel 5mL
	Affected / at Risk (%)	# Events
Total	2/4 (50%)
Vascular disorders
subdural hematoma	2/4 (50%)	2
Other (Not Including Serious) Adverse Events
	OncoGel 5mL
	Affected / at Risk (%)	# Events
Total	0/4 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.